Cleared Traditional

K212425 - MicroTrend System (FDA 510(k) Clearance)

Class II Anesthesiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K212425 · Exostat Medical, Inc. · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2024
Decision
1191d
Days
Class 2
Risk

K212425 is an FDA 510(k) clearance for the MicroTrend System. Classified as Analyzer, Gas, Carbon-dioxide, Gaseous-phase (product code CCK), Class II - Special Controls.

Submitted by Exostat Medical, Inc. (Prior Lake, US). The FDA issued a Cleared decision on November 7, 2024 after a review of 1191 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.1400 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Anesthesiology submissions.

View all Exostat Medical, Inc. devices

Submission Details

510(k) Number K212425 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 04, 2021
Decision Date November 07, 2024
Days to Decision 1191 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
1052d slower than avg
Panel avg: 139d · This submission: 1191d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CCK Analyzer, Gas, Carbon-dioxide, Gaseous-phase
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 868.1400
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Anesthesiology devices follow this clearance model.

Regulatory Peers - CCK Analyzer, Gas, Carbon-dioxide, Gaseous-phase

All 304
Devices cleared under the same product code (CCK) and FDA review panel - the closest regulatory comparables to K212425.
Capnostream™35 Portable Respiratory Monitor (PM35MN)
K253030 · Covidien, LLC · May 2026
Medical Gas Analyzer (AG200)
K250148 · Prior Care Science Technology, Ltd. · Aug 2025
TG-980P CO2 Sensor Kit (TG-980P)
K243956 · Nihon Kohden Corporation · Jun 2025
0184 CO2 Sampling line
K251216 · Barbaras Development, Inc. · Jun 2025
AIM (N/A)
K240937 · Inventeur, LLC · Dec 2024
AirLife™ Open Et Oxygen Mask, AirLife™ Open Et+ Oxygen Mask
K230915 · Vyaire Medical, Inc. · Nov 2024